Search Results
Your search for world matches 4351 pages
Showing 201 - 250ASCO Honors Karen Eubanks Jackson of Sisters Network® Inc. With 2025 Patient Advocate Award
Karen Eubanks Jackson, founder and Chief Executive Officer of Sisters Network® Inc. (SNI), has been named the recipient of the 2025 Patient Advocate Award by ASCO, Conquer Cancer, and the ASCO Foundation. The awards ceremony was held during the 2025 ASCO Annual Meeting. (See a video with Ms....
In Second-Line Setting, T-DXd Improves Survival Outcomes in HER2-Positive Gastric or Gastroesophageal Junction Cancer
In the phase III DESTINY-Gastric04 trial, use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was compared head to head with the monoclonal antibody ramucirumab and paclitaxel in patients with previously treated, HER2-positive metastatic gastric or gastroesophageal junction...
Early ESR1 Mutation Detection and Therapy Switch in Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer
Early detection of an ESR1 mutation, leading to a switch of endocrine therapy, led to an almost doubling in progression-free survival in the SERENA-6 trial, the global registrational study in patients with metastatic breast cancer for the investigational oral selective estrogen receptor degrader...
ASH 2025 Awardees: Hematologists to Be Honored With Highest Distinctions
The American Society of Hematology (ASH) announced that it will recognize 11 hematologists who have made notable contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, from December 6–9, 2025. The...
Establishing Novel Models of Interdisciplinary Care to Improve Survival Outcomes in Patients With Cancer
Internationally renowned for her decades-long pioneering research in pancreatic cancer, in 2024, Diane M. Simeone, MD, left her positions as the Laura and Isaac Perlmutter Professor of Surgery and Pathology; Director, Pancreatic Cancer Center; and Associate Director of the Perlmutter Cancer Center...
Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stephen R. Grobmyer, MD, FACS, about his clinical and research career in oncology, the challenges and rewards of moving to Abu Dhabi and building a state-of-the-art cancer center, and...
Do the Benefits of Fluoropyrimidine for GI Cancers Outweigh Cardiovascular Risk?
Patients with gastrointestinal cancer treated with fluoropyrimidine chemotherapy benefit from an almost eightfold reduction in the risk of all-cause mortality, despite a slight increase in the risk for cardiovascular toxicity, according to recent findings published by Abiodun et al in JACC:...
Self-Collection Kit Mailings May Increase Cervical Cancer Screening Rates in Underserved Settings
Mail-in self-collection kits for human papillomavirus (HPV) were found to be effective at increasing cervical cancer screening rates compared with standard telephone reminders alone in a safety-net health-care setting, according to results from the PRESTIS trial published in JAMA Internal Medicine. ...
How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research
Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...
Improving the Alliance Between Oncologists and Primary Care Providers: A Call for Collaborative Action
Experts and patients alike would agree that navigating the current fragmented U.S. health-care system is not an easy task. One component of that disconnection may center on the relationship between oncology and primary care. The benefits of collaboration between oncologists and primary care...
Pathology Machine-Learning Models and Diagnosis of Nonmelanoma Skin Cancers in Resource-Limited Settings
Artificial intelligence (AI) models, which were pretrained on vast data sets, outperformed a standard baseline model in identifying nonmelanoma skin cancers from digital images of tissue samples, based on a session presented during the 2025 American Association for Cancer Research (AACR) Annual...
Structured Exercise Program Improves Survival Outcomes in Patients With Stage III or High-Risk Stage II Colon Cancer
A 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improved disease-free survival and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III or high-risk stage II colon cancer. These...
Study Finds GLP-1RAs May Lower Risk of Obesity-Related Cancers vs DPP-4 Inhibitors in Adults With Diabetes and Obesity
Studies have shown that being overweight or having obesity increases the risk of developing more than a dozen cancers, including meningioma, multiple myeloma, esophageal, thyroid, breast, gallbladder, stomach, liver, pancreas, kidney, ovarian, uterus, and colorectal.1 The presence of excess body...
SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC
Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care treatments for patients with stage IV or recurrent non–small cell lung cancer (NSCLC) who previously...
ASCO 2025: Structured Exercise Program Improves Survival, Outcomes in Some Patients With Colon Cancer
A phase III study has found that a 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improves disease-free and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III and high-risk stage II...
William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated...
ASCO 2025: Alcohol-Related Cancer Deaths Are on the Rise in the United States
A new study led by experts at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is the first to look at trends over time in alcohol-linked cancer mortality across the United States. The findings were presented at the 2025 ASCO Annual Meeting (Abstract ...
How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to help others was ingrained in her from a very early age. Growing up in New Delhi, India, where...
Alcohol May Be Linked to Higher Risk of Pancreatic Cancer
Investigators may have uncovered a modest but potentially significant association between alcohol consumption and the risk of developing pancreatic cancer, according to a recent study published by Naudin et al in PLOS Medicine. Background Pancreatic cancer is the twelfth most common cancer type...
Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent one, associated with a near-normal life expectancy on optimal tyrosine kinase inhibitor...
I Have Stage IV Lung Cancer and Still Consider Myself the Luckiest Man in the World
Although I have spent the past 2 decades of my medical career as a primary care physician, educator, and researcher in conditions that disproportionately affect people of Asian descent, including lung cancer, I was still unprepared to hear the words “You have stage IV non–small cell lung...
ASCO Congratulates 2025 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2025 ASCO Annual Meeting. “The recipients of this year’s...
W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of OSUCCC-James
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....
Together, We’re Building a Better Future for People With Cancer and for Our Profession
For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st President and what I know our more than 50,000 members stand for. And I believe we will get there...
The Power of Translational Science to Transform the Lives of Patients Worldwide
Despite a 30-year history as an ASCO volunteer, for Eric J. Small, MD, FASCO, this past year as President-Elect has opened new perspectives on the organization he will soon lead as ASCO’s 62nd President, effective during the 2025 ASCO Annual Meeting, May 30–June 3, 2025, in Chicago. After serving...
GLP-1 RAs May Lower Risk of Obesity-Related Cancers
Studies have shown that having overweight or obesity increases the risk of developing more than a dozen cancers, including meningioma; multiple myeloma; and esophageal, thyroid, breast, gallbladder, stomach, liver, pancreatic, kidney, ovarian, uterine, and colorectal cancers. The presence of excess ...
Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma
In a Chinese phase III trial (APOLLO) reported in The Lancet Oncology, Zhou et al evaluated whether the combination of the multikinase inhibitor anlotinib and the PD-1 inhibitor penpulimab improved progression-free survival and overall survival vs sorafenib in first-line treatment of unresectable...
Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision
For postmenopausal women with hormone receptor–positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider surgical margins (≥ 1 mm or ≥ 2 mm) may not be necessary, according to data presented ...
Annual or Biennial Multicancer Early Detection Screening Improves Patient Outcomes
The addition of multi-cancer early detection screening using a single blood sample improved patient outcomes whether conducted on an annual or every 2-year basis, according to findings from a modelling study published in BMJ Open. With earlier detection of disease progression, many cancers could...
Collaborative Strategy Involving AI, Human Task-Sharing Could Help Minimize Mammogram Costs
When screening for breast cancer, the most effective strategy to utilize artificial intelligence (AI) may involve collaboration with human radiologists, according to a recent study published by Ahsen et al in Nature Communications. The findings could help shape how hospitals and clinics integrate...
Remembering Roswell Park Leader Thomas B. Tomasi, Jr, MD, PhD
Thomas B. Tomasi, Jr, MD, PhD, who led Roswell Park Comprehensive Cancer Center as President and Chief Executive Officer from 1986 to 1996, died on March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers. The pinnacle of ...
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
Radiotherapy for Prostate Cancer: 2- vs 8-Week Course
The phase III HYPO-RT-PC trial has shown that a 2-week course of radiotherapy for localized prostate cancer—also known as ultra-hypofractionated radiotherapy—may be just as safe and effective as the traditional 8-week schedule—even 10 years after treatment. The findings were presented at the 2025...
AACR 2025: AI-Driven Model For Identifying Cancer Cachexia
Use of a multimodal deep learning–based model led to more accurate and earlier identifications of cancer cachexia than standard clinical and radiological observations, according to findings presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (Abstract 1143)....
AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings
Artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers from digital images of tissue samples, according to new findings presented by Song et al at the 2025 American Association for Cancer Research (AACR)...
Addition of Neoadjuvant/Adjuvant Pembrolizumab Significantly Improves Outcomes in Locally Advanced HNSCC
The addition of neoadjuvant and adjuvant pembrolizumab to standard-of-care therapy significantly improved event-free survival over the standard of care alone for patients with locally advanced head and neck cancer in the phase III KEYNOTE-689 trial, according to results presented at the American...
W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of The Ohio State’s James Cancer Hospital and Solove Research Institute
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....
Karen E. Knudsen, MBA, PhD, Appointed Chief Executive Officer of the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO). A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen joins PICI at a pivotal time ...
Hyperefficient and Super-Digitized Health Care: Where Is the Smile?
A few weeks ago, a family member underwent a minor outpatient operative procedure. From a few weeks before the scheduled date of the procedure, multiple text messages and e-mails were forwarded to provide preparatory instructions for the procedure. The day before the procedure, another...
Role of Pathologists in Improving Access to Safer, More Effective Allogeneic Cell Therapies
Researchers are working to accelerate the clinical adoption of novel allogeneic cell therapies to improve cancer care and treatment, according to a new report from the College of American Pathologists (CAP). Background Allogeneic cell therapy—which uses cells from a healthy donor rather than a...
CAP Issues New and Updated Cancer Protocols
New protocols for endocrine tumors and updated existing protocols for breast cancer diagnoses are now available from the College of American Pathologists (CAP). These and other updates to protocols reflect the latest scientific advancements, ensuring that pathology reports provide oncologists with...
Early-Life Exposure to Environmental Carcinogens May Increase Risk of Pediatric Papillary Thyroid Cancer
Perinatal and early-life exposure to ambient fine particulate matter air pollution (PM2.5) and outdoor artificial light at night (O-ALAN) may be associated with a statistically significant increased risk of papillary thyroid cancer in children and young adults up to 19 years old, according to the...
Most Pediatric Cancer Deaths Occur in Regions of Conflict
Almost 60% of all deaths from pediatric cancers occur in regions of armed conflict, according to the results of a study published in The Lancet Oncology. Investigators from St. Jude Children’s Research Hospital, Duke University, and other institutions sought to reveal the relationship between...
Characteristics of Nasopharyngeal Carcinoma in the United States
In a single-center study reported in JAMA Network Open, Alsavaf et al attempted to identify patient characteristics and treatment outcomes of nasopharyngeal carcinoma in the United States, a nonendemic region of the disease. Study Details The retrospective cohort study included patients with...
Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis
A novel machine learning model may outperform standard statistical models in identifying and stratifying transplantation risk among patients with myelofibrosis, according to a recent study published by Hernández-Boluda et al in Blood. Background Although there are several therapies available to...
Parker Institute for Cancer Immunotherapy Names New CEO
The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as the new Chief Executive Officer (CEO) of the institute. A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen will take on her...
Prevalence of Genetic Testing in Women With Ovarian Cancer
Investigators have found that nearly 50% of women diagnosed with ovarian cancer may not be receiving the genetic testing that could help guide their treatment and potentially improve outcomes, according to a recent report conducted by the Ovarian Cancer Research Alliance (OCRA) and Komodo Health....
Can a Urine Test Minimize Postoperative Scans for RCC Recurrence?
A simple urine test could accurately detect clear cell renal cell carcinoma (RCC) recurrence at an early stage, potentially sparing patients from undergoing invasive scans and enabling quicker access to treatment, according to new findings presented by Dabestani et al at the European Association of ...
Conexiant Signs Partnership Deal With Elsevier to Enhance Society Marketing and Member Engagement Solutions
Conexiant has partnered with Elsevier to deliver world-class solutions and sales execution to more than 100 global societies and associations covering more than 25 core specialties in the health-care space. This collaboration marks a significant step forward in delivering innovative advertising,...
Confronting the Growing Global Threat of Antimicrobial Resistance in Cancer Care
The dire warnings about the lethal consequences of unchecked antimicrobial resistance are getting louder and becoming more urgent. The U.S. Department of Health and Human Services has called antimicrobial resistance “one of the most important health security threats of our time,” with at least 2.8...
